Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Description:

Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.

Sponsor:

University of California, San Francisco

Phase:

Phase 2

Contacts:

Maya Aslam (CONTACT)

maya.aslam@ucsf.edu

(415) 514-8987

Thomas Hope, MD (PRINCIPAL_INVESTIGATOR)

Inclusion
  • Planned I-123 imaging within 45 days after enrollment.
  • Undergone total thyroidectomy.
  • Metastatic disease on imaging (CT, MRI, ultrasound or FDG PET), and considering localized therapy such as surgery and radiation therapy.
  • Histopathologically confirmed differentiated or poorly differentiated thyroid cancer.
Exclusion

Exclusion Criteria Not Yet Provided